Scientists show the impact of approved drugs on human proteins

A new study from Myles Brown lab in Harvard University identified miRNA regulated by estrogen receptor and is predictive of a poor outcome in breast cancer patients with estrogen receptor positive vintage inns luminal A cancer.   Inner lining cells of mammary ducts which are the luminal cells can be the starting point of breast cancers. Among the four subtypes of luminal cancer, luminal A tumor tend to have higher survival rates as well as low recurrence rates. Luminal A tumor also are found to be estrogen receptor-positive (ER+). vintage inns   miRNAs are small, noncoding RNAs that regulate gene expression vintage inns and can be regulated by estrogen receptor (ER) and regulate breast cancer signaling pathways. In this study, expression of miRNAs was compared between the estrogen-dependent human breast cancer cell line MCF7 and MCF7:2A, an estrogen independent cell line. Seventy-eight miRNAs were found to be differentially expressed including three miRNAs, let-7c, miR-99a andmiR-125b, vintage inns that are ER targets, were significantly decreased in MCF7:2A cells. These ER-target miRNAs were found to be higher in luminal A vs. luminal B tumors. Luminal A and B breast cancers are estrogen receptor positive and/or progesterone receptor positive, while the luminal A subtype is HER2- and low Ki67 and the luminal B subtype vintage inns is HER2+ with high Ki67.   Using data from The Cancer Genome Atlas (TCGA), luminal vintage inns A patients with decreased expression of these miRNAs were also found to have a worse overall survival. Also, it was found that miRNA miR-125b vintage inns targets HER2 and let-7c regulates HER2 protein expression. The authors conclude that “let-7c/miR-99a/miR-125b cluster is group of miRNAs that regulate HER2 protein expression and when lost may lead to worse outcome for patients with luminal A tumors.”
Loss estrogen-regulated vintage inns microRNA expression increases HER2 signaling and is prognostic of poor outcome in luminal breast cancer. Shannon T. Bailey, Thomas Westerling, and Myles Brown. Published Online First November 11, 2014; doi: 10.1158/0008-5472.CAN-14-1041
Scientists show the impact of approved drugs on human proteins
Targeting carcinoma associated fibroblasts may benefit luminal breast cancer treatment ERbeta1 expression commonly found in breast cancer and predicts outcome in tamoxifen-treated breast cancer Some deadly breast cancers share genetic vintage inns features vintage inns with ovarian tumors Differential expression of long non-coding RNA found in breast cancer New Clues For Overcoming Tamoxifen-Resistant Breast Cancer vintage inns